Close Menu
  • Business
  • World News
    • United States of America
    • Europe
    • Asia
    • Oceania
  • Technology
  • Sports
  • Money
  • Health
  • Life & Style
  • Shopping

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025
Facebook X (Twitter) Instagram
Daily News
Facebook X (Twitter) Instagram
Subscribe
  • Home
  • Business

    What Size Skip Do You Need for Your Project?

    May 12, 2025

    Introduction to Share CFDs: Understanding the Basics

    December 2, 2024

    Importance of Proper Disposal in Spray Foam Removal

    August 26, 2024

    The Underlying Dynamics of Italy’s Euro: Economic Policies and Market Implications

    June 27, 2024

    The Pros and Cons of Payday Loans: Understanding the Risks and Benefits

    March 27, 2024
  • World News

    HNA Group Chairman Chen Feng Gives Speech at 2015 WTTC Global Summit: China Sees Huge Tourism Cooperation Opportunities with Europe

    October 24, 2020

    Greyrock Direct Fuel Production(TM) Recognized by the World Bank as Most Advanced Technology for Gas-to-Liquids

    September 28, 2020

    DJI to Open Flagship Store in Hong Kong

    August 29, 2020

    Micreos Secures Euros 12 Million for New Products Containing Staphefekt; Alternative to Antibiotics Can Help Millions

    June 18, 2020

    NetEase Debuts New Publicity Video in Shibuya, Triggers Speculation in Japan Game Industry

    April 19, 2020
  • Technology
  • Sports
  • Money
  • Health
  • Life & Style
  • Shopping
Daily News
Home»Business»Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer
Business

Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

AndrewBy AndrewSeptember 12, 2014No Comments5 Mins Read0 Views
Facebook Twitter Pinterest Telegram LinkedIn Tumblr Copy Link Email
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link

 Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).

    Luciano Rossetti, Global Head of Research & Development at Merck Serono, said: “While the data from the exploratory subgroup analysis in the START trial[1] generated a reasonable hypothesis to warrant additional study, the results of the recent trial in Japanese patients decreased the probability of current studies to reach their goals. Therefore, we have decided to discontinue the development of tecemotide as a monotherapy in NSCLC in order to refocus our efforts on other promising candidates in our pipeline, like our anti-PD-L1 antibody MSB0010718C. Merck Serono remains committed to developing new treatment options for patients with difficult-to-treat cancers.”

    The company’s decision to discontinue the current clinical program in NSCLC, which includes the Phase III START2 and INSPIRE studies, follows recent results from a planned analysis of EMR 63325-009, a randomized, double-blind, placebo-controlled Phase I/II study in Japanese patients with Stage III unresectable, locally advanced NSCLC who had received concurrent or sequential chemoradiotherapy (CRT), with a minimum of two cycles of platinum-based chemotherapy and radiation dose greater than or equal to50 Gy. Of the patients included in the Phase II part of the study, the majority had received concurrent CRT. The results indicate that no effect has been observed for either the primary endpoint, overall survival (OS), or for any of the secondary endpoints (progression-free survival [PFS], time to progression [TTP] and time to treatment failure). An analysis of the reported adverse events has not identified a clinically meaningful difference in the frequency between treatment groups. Although the trial was not powered to demonstrate a statistically significant difference in benefit between the two arms, Merck Serono made the recommendation to stop the investigational treatment for patients in the EMR 63325-009 study in Japan.

    Merck Serono has made the decision to discontinue all other Merck Serono-sponsored clinical trials with tecemotide in NSCLC worldwide. Those patients on active treatment with tecemotide can undergo an individual assessment by their treating physician and apply to receive further treatment outside of the studies. The company will continue to supply tecemotide for ongoing investigator-sponsored trials in other indications in accordance with Merck’s agreements with the sponsors of these studies.

    Merck Serono continues to evaluate a number of investigational compounds for difficult-to-treat cancers, and remains committed to improving the lives of cancer patients and their families.

    References

    1) Butts C, et al. Lancet Oncol 2014;15(1):59-68.

    About tecemotide

    Tecemotide is an investigational MUC1 antigen-specific cancer immunotherapy that is designed to stimulate the body’s immune system to identify and target cells expressing the cell-surface glycoprotein MUC1. MUC1 is expressed in many cancers, including NSCLC, and has multiple roles in tumor growth and survival. Tecemotide was being investigated in the Phase III START2, START and INSPIRE trials for the treatment of unresectable, locally advanced Stage III NSCLC.

    Merck obtained the exclusive worldwide rights for development and commercialization of tecemotide from Oncothyreon Inc., Seattle, Washington, U.S., in 2007, in an agreement replacing prior collaboration and supply agreements originally entered in 2001. In Japan, Merck entered into a co-development and co-marketing agreement for tecemotide with Ono Pharmaceutical Co., Ltd., Osaka, Japan.

    The START2 study is a Phase III, multicenter, 1:1 randomized, double-blind, placebo-controlled clinical trial designed to assess the efficacy, safety and tolerability of tecemotide in patients suffering from unresectable, locally advanced (Stage IIIA or IIIB) NSCLC who have had a response or stable disease after at least two cycles of platinum-based concurrent CRT. Concurrent CRT – a combination of chemotherapy and radiotherapy given at the same time – is the current standard of care for most of these patients. The study, which began in April 2014, expected to recruit about 1,000 patients. The study’s primary endpoint is OS. Secondary endpoints include time to symptom progression, PFS and TTP.

    The basis for the START2 trial was the outcome of the initial START study. START did not meet the primary endpoint of demonstrating an improved OS with tecemotide compared with placebo in the overall patient population (n=1,239). Median OS was 25.6 months for patients in the tecemotide group compared with 22.3 months for those in the placebo group (adjusted hazard ratio [HR]: 0.88; 95% confidence interval [CI]: 0.75-1.03; p=0.123). However, data from an exploratory analysis of a pre-defined subgroup of patients in the START trial, who received tecemotide after concurrent CRT, showed that these patients achieved a median OS of 30.8 months versus 20.6 months in patients treated with placebo (n=806; HR: 0.78; 95% CI: 0.64-0.95; p=0.016).

    INSPIRE is a Phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety and tolerability of tecemotide in patients suffering from unresectable, locally advanced Stage IIIA or IIIB NSCLC who have had a response or stable disease after at least two cycles of platinum-based concurrent CRT. INSPIRE expected to recruit approximately 500 Stage III NSCLC patients across China, Hong Kong, Korea, Singapore and Taiwan.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of EUR 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Telegram Email Copy Link
Andrew

Related Posts

What Size Skip Do You Need for Your Project?

May 12, 2025

Introduction to Share CFDs: Understanding the Basics

December 2, 2024

Importance of Proper Disposal in Spray Foam Removal

August 26, 2024

Comments are closed.

Featured Posts

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Don't Miss!

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Top Posts

Importance of Proper Disposal in Spray Foam Removal

August 26, 202418 Views

Introduction to Share CFDs: Understanding the Basics

December 2, 202411 Views

PVC Windows and Doors still the most popular choice

October 12, 201211 Views

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 202510 Views
Don't Miss

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 20253 Mins Read10 Views

Swing trading offers a practical balance between day trading and long-term investing. It gives traders…

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Stay In Touch
  • Facebook
  • Twitter
  • Instagram
  • YouTube

Subscribe to Updates

Get the latest creative news from SmartMag about art & design.

About Us
About Us

Daily News blog provides you the latest news, guide and tips, related information and issues about the Automotive, Business, Technology, Sports, Life & Style, News Photography, and Shopping etc.

Facebook X (Twitter) Instagram
Our Picks

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025
Most Popular

Mark Ingram wins 2009 Heisman Trophy

December 15, 20090 Views

Dubai receives bailout from Abu Dhabi

December 15, 20090 Views

North Korean weapons seized in Thailand

December 15, 20090 Views
Daily News
  • Home
  • About
  • Contact
  • Privacy Policy
Copyright © 2019-2025. Daily News..

Type above and press Enter to search. Press Esc to cancel.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT